vTv Therapeutics Inc (VTVT) - Total Assets
Based on the latest financial reports, vTv Therapeutics Inc (VTVT) holds total assets worth $99.49 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of vTv Therapeutics Inc for net asset value and shareholders' equity analysis.
vTv Therapeutics Inc - Total Assets Trend (2013–2024)
This chart illustrates how vTv Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
vTv Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
vTv Therapeutics Inc's total assets of $99.49 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.0% |
| Accounts Receivable | $62.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how vTv Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VTVT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: vTv Therapeutics Inc's current assets represent 99.6% of total assets in 2024, an increase from 15.6% in 2013.
- Cash Position: Cash and equivalents constituted 96.0% of total assets in 2024, up from 7.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
vTv Therapeutics Inc Competitors by Total Assets
Key competitors of vTv Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
vTv Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.79 | 6.69 | 1.13 |
| Quick Ratio | 9.79 | 6.69 | 1.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $89.29 Million | $36.53 Million | $825.00K |
vTv Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between vTv Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 3.26 |
| Asset Growth Rate (YoY) | 247.3% |
| Total Assets | $38.27 Million |
| Market Capitalization | $124.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values vTv Therapeutics Inc's assets at a significant premium (3.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: vTv Therapeutics Inc's assets grew by 247.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for vTv Therapeutics Inc (2013–2024)
The table below shows the annual total assets of vTv Therapeutics Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $38.27 Million | +247.30% |
| 2023-12-31 | $11.02 Million | -66.85% |
| 2022-12-31 | $33.24 Million | +30.48% |
| 2021-12-31 | $25.47 Million | +72.25% |
| 2020-12-31 | $14.79 Million | +59.61% |
| 2019-12-31 | $9.27 Million | +8.26% |
| 2018-12-31 | $8.56 Million | -69.34% |
| 2017-12-31 | $27.92 Million | -48.77% |
| 2016-12-31 | $54.49 Million | -40.46% |
| 2015-12-31 | $91.53 Million | +606.76% |
| 2014-12-31 | $12.95 Million | -16.47% |
| 2013-12-31 | $15.50 Million | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more